BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($2.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Trading Down 0.3 %
BCTX traded down $0.01 during trading on Wednesday, hitting $3.65. 26,695 shares of the company traded hands, compared to its average volume of 191,580. The company has a market cap of $13.54 million, a PE ratio of -0.27 and a beta of 1.71. The stock’s 50-day simple moving average is $5.10 and its two-hundred day simple moving average is $9.28. BriaCell Therapeutics has a 1 year low of $3.00 and a 1 year high of $45.60.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their target price on BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Consumer Discretionary Stocks Explained
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- The Most Important Warren Buffett Stock for Investors: His Own
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What does consumer price index measure?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
